Cytokinetics, Inc. Stock Nasdaq
Equities
US23282W1009
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
06-24 | JPMorgan Cuts Price Target on Cytokinetics to $65 From $77, Maintains Overweight Rating | MT |
06-17 | Cytokinetics Insider Sold Shares Worth $262,750, According to a Recent SEC Filing | MT |
Sales 2024 * | 32.14M 43.96M | Sales 2025 * | 72.93M 99.75M | Capitalization | 6.3B 8.61B |
---|---|---|---|---|---|
Net income 2024 * | -490M -670M | Net income 2025 * | -494M -676M | EV / Sales 2024 * | 181 x |
Net cash position 2024 * | 464M 635M | Net cash position 2025 * | 474M 649M | EV / Sales 2025 * | 79.8 x |
P/E ratio 2024 * |
-12.2
x | P/E ratio 2025 * |
-12.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.5% |
Latest transcript on Cytokinetics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Robert Blum
CEO | Chief Executive Officer | 60 | 98-06-30 |
Kari Loeser
CMP | Compliance Officer | - | 21-10-31 |
Stuart Kupfer
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy Wysenski
BRD | Director/Board Member | 66 | 20-11-19 |
Edward Kaye
BRD | Director/Board Member | 75 | 16-05-19 |
Santo Costa
BRD | Director/Board Member | 78 | 10-09-30 |
1st Jan change | Capi. | |
---|---|---|
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |